The Significance of Histopathological And Immunohistochemical Differences of Usual Ductal Hiperplasia, Atypical Ductal Hyperplasia and Ductal Carcinoma In Situ

Original article

Nemanja Lilić, Duško Dunđerović,Vanja Lelas, Dijana Kovačević, Nina Kovačić Mirjana Prvanović

1–6

https://doi.org/10.5937/medrec2601001L

ORCID iDs:     Nemanja Lilić                     https://orcid.org/0009-0002-1413-2875

Duško Dunđerović       https://orcid.org/0000-0001-9708-2089
Vanja Lelas                 N/A
Dijana Kovačević         N/A
Nina Kovačić               N/A
Mirjana Prvanović        https://orcid.org/0009-0005-1714-4363

Abstract

Ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH) can precede invasive breast cancer. Early detection and differential diagnosis of these lesions improves prognosis. Usual ductal hyperplasia (UDH) has low malignant potential. There differential diagnosis is crucial. The aim was to analyze the gender and age of patients, differences in the histopathological and immunohistochemical presentation of UDH, ADH, and DCIS. This retrospective study included archived biopsy samples of 52 patients analyzed at the Institute of Pathology. Data on patient gender and age were obtained from medical records. H/E slides, and immunohistochemical markers (ER, PR, HER2, Ki-67, CK5/6) were used. Data was analyzed using descriptive statistical methods. Average age was 64.1 years. Out of the 52 patients, 49 were female, and 3 were male. The most common finding was DCIS. Isolated DCIS was found in 17% of patients, while 69% had DCIS associated with invasive carcinoma. ADH was isolated in 7% of patients, while 2% had ADH associated with DCIS and invasive carcinoma. UDH was present in 2% of patients. One male patient had UDH, while the other two had DCIS. Among women, the most common finding was DCIS associated with invasive carcinoma. ER was positive in 71.15% of cases and negative in 28.8%. PR was positive in 53.8% and negative in 46.2%. HER2 was positive in 38.4% and negative in 61.6%. Triple-negative status was observed in 5.76% of cases. All patients with UDH were positive for the CK5/6 marker, which was absent in ADH and DCIS. This study highlights the importance of early diagnosis while immunohistochemistry, especially CK5/6 and ER markers, plays a critical role.

Key words: usual ductal hyperplasia, atypical ductal hyperplasia, ductal carcinoma in situ, immunohistochemistry

Full text 

Literatura

  1. Menon G, Alkabban FM, Ferguson T. Breast Cancer. 2024 Feb 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.
  2. Smolarz B, Nowak AZ, Romanowicz H. Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers (Basel) 2022;23(10):2569.
  3. Casaubon JT, Kashyap S, Regan JP. BRCA1 and BRCA2 Mutations. 2023 Jul 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.
  4. Wei S. Hormone receptors in breast cancer: An update on the uncommon subtypes. Pathol Res Pract 2023;250:e154791
  5. Krishnamurti U, Silverman JF. HER2 in breast cancer: a review and update. Adv Anat Pathol 2014;21(2):100-7.
  6. Derakhshan F, Reis-Filho JS. Pathogenesis of Triple-Negative Breast Cancer. Annu Rev Pathol 2022;17:181-204.
  7. Dass SA, Tan KL, Selva Rajan R, Mokhtar NF, Mohd Adzmi ER, Wan Abdul Rahman WF, et al. Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities. Medicina (Kaunas) 2021;12(1):62.
  8. Jahn SW, Kashofer K, Thüringer A, Abete L, Winter E, Eidenhammer S et al. Mutation Profiling of Usual Ductal Hyperplasia of the Breast Reveals Activating Mutations Predominantly at Different Levels of the PI3K/AKT/mTOR Pathway. Am J Pathol 2016;186(1):15-23.
  9. Lerias S, Lerwill M. Usual ductal hyperplasia. PathologyOutlines.com website
  10. Rella R, Conti M, Borghetti A, Belli P, Morciano F, Rossati C, et al. Atypical ductal hyperplasia on vacuum-assisted breast biopsy: a scoring system to predict the risk of upgrade to malignancy. Radiol Med 2024;129(1):38-47.
  11. Tomlinson-Hansen SE, Khan M, Cassaro S. Atypical Ductal Hyperplasia. 2023 Apr 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.
  12. Coopey SB, Kartal K, Li C, Yala A, Barzilay R, Faulkner HR, et al. Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk? Breast Cancer Res Treat 2019;175(1):1-4.
  13. Niewoehner CB, Schorer AE. Gynaecomastia and breast cancer in men. BMJ 2008;29 (7646):709-13.
  14. Miceli R, Mercado CL, Hernandez O, Chhor C. Active Surveillance for Atypical Ductal Hyperplasia and Ductal Carcinoma In Situ. J Breast Imaging 2023;28(4):396-415.
  15. Fu F, Gilmore RC, Jacobs LK. Ductal Carcinoma In Situ. Surg Clin North Am 2018;98(4):725-45.
  16. Grimm LJ, Rahbar H, Abdelmalak M, Hall AH, Ryser MD. Ductal Carcinoma in Situ: State-of-the-Art Review. Radiology 2022;302(2):246-55.
  17. Pinder SE. Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation. Mod Pathol 2010;23 Suppl 2:S8-13.
  18. Badve SS, Gökmen-Polar Y. Ductal carcinoma in situ of breast: update. Pathology 2019;51(6):563-9.
  19. Bychkovsky BL, Myers S, Warren LEG, De Placido P, Parsons HA. Ductal Carcinoma in situ. Hematol Oncol Clin North Am 2024;38(4):831-49.
  20. Boecker W, Moll R, Dervan P, Buerger H, Poremba C, Diallo RI, et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol 2002;198(4):458-67.
  21. Martinez AP, Cohen C, Hanley KZ, Li XB. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ. Arch Pathol Lab Med 2016;140(7):686-9.
  22. Bomeisl P, Gilmore H. Spectrum of atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS): Diagnostic challenges. Semin Diagn Pathol 2024;41(6):252-7.
  23. Daoud SA, Ismail WM, Abdelhamid MS, Nabil TM, Daoud SA. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast. Asian Pac J Cancer Prev 2016;17(8):3733-6.